A. Amatucci

发表

Integrin α1β1 and Transforming Growth Factor-β1 Play Distinct Roles in Alport Glomerular Pathogenesis and Serve as Dual Targets for Metabolic Therapy

R. Kalluri, Caroline A. Miller, H. Gardner, 2000 .

Identification of Novel Fibrosis Modifiers by In Vivo siRNA Silencing

Daniel G. Anderson, Kevin J. Kauffman, D. Brenner, 2017, Molecular therapy. Nucleic acids.

Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy.

R. Kalluri, C. Miller, H. Gardner, 2000, The American journal of pathology.

Attenuated liver fibrosis in the absence of B cells.

M. Shlomchik, V. Koteliansky, S. Casola, 2005, The Journal of clinical investigation.

Development of an Fn14 agonistic antibody as an anti-tumor agent

P. Schneider, E. Day, Y. Hsu, 2011, mAbs.

Recombinant ST2 boosts hepatic Th2 response in vivo

K. Gilbride, T. Novobrantseva, P. Hochman, 2007, Journal of leukocyte biology.

TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease.

G. Karaca, S. Szak, J. Duffield, 2016, Journal of the American Society of Nephrology : JASN.

Murine monoclonal antibody elicited with antibiotic-exposed Escherichia coli exerts protective capacity in experimental bacterial infections.

A. Bartolazzi, G. Raponi, M. T. Lun, 1994, Journal of medical microbiology.

TWEAK signals through JAK-STAT to induce tumor cell apoptosis.

Lan Wu, J. Michaelson, S. Ho, 2013, Cytokine.

Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

L. Croner, A. Lugovskoy, Xiufeng Wu, 2010, Protein engineering, design & selection : PEDS.

Characterisation and protel ity of monoclonal antibodies elicited in mice tive capal against protein epitopes of antibiotic-exposed Escherichia coli

G. Raponi, M. T. Lun, P. Natali, 1997 .

Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation‡

C. Weston, G. Reynolds, D. Adams, 2016, The Journal of pathology.

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTβR

A. Lugovskoy, G. Farrington, J. Browning, 2009 .

Characterisation and protective capacity of monoclonal antibodies elicited in mice against protein epitopes of antibiotic-exposed Escherichia coli.

G. Raponi, M. T. Lun, C. Mancini, 1997, Journal of medical microbiology.

Pathological activation of canonical nuclear-factor κB by synergy of tumor necrosis factor α and TNF-like weak inducer of apoptosis in mouse acute colitis.

L. Burkly, J. Michaelson, T. Dohi, 2014, Cytokine.

Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.

A. Lugovskoy, G. Farrington, J. Browning, 2009, mAbs.